CDMRP: Tick-Borne Disease Research Program (TBDRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 Tick-Borne Disease Research Program (TBDRP) pre-announcement was released by the Congressionally Directed Medical Research Programs (CDMRP) on February 12, 2026. This pre-announcement signals anticipated funding opportunities aimed at high-impact research to prevent, detect, and resolve Lyme disease and other tick-borne diseases that affect Service Members, Veterans, families, and the general public. Funding opportunity announcements (FOAs) — including pre-application and full application deadlines — have not yet been released and must be monitored on Grants.gov and eBRAP.

How much funding would I receive?

Award-specific maximums from the pre-announcement:

• Idea Development Award – Up to $800,000 total costs over up to 3 years.

• Idea Development Award – Career Development Option – Up to $550,000 total costs over up to 3 years.

• Therapeutic/Diagnostic Research Award – Up to $1,325,000 total costs over up to 3 years.

What could I use the funding for?

Funding is intended to support innovative, high-impact research addressing tick-borne diseases. The pre-announcement defines mechanism-specific focus areas:

A) Idea Development Award

Pathogenesis

• Assess interactions among tick-borne pathogens (emphasis Lyme and co-infections)

• Study persistent clinical manifestations (neurologic symptoms encouraged)

• Studies on maternal health, pregnancy outcomes, congenital infections

Treatment

• Proof-of-concept for novel therapeutics or repurposing existing compounds

• Target identification/validation and early refinement of therapeutic candidates

Diagnosis

• Development/optimization of improved diagnostics for:

  • Single or multiple tick-borne pathogens (priority on direct detection of Borrelia burgdorferi)

  • Distinguish active Lyme infection from past exposure

  • Detect/diagnose maternal-to-fetal transmission, including relevant animal models

B) Therapeutic/Diagnostic Research Award

• Treatment – Evaluation/refinement of therapeutic candidates, including PK/PD and toxicology; designed to advance early/preclinical drug development.

• Diagnosis – Validation of novel diagnostics capable of single or multi-pathogen detection, distinguishing active from past infection, and detecting maternal-to-fetal transmission pathways.

Are there any additional benefits I would receive?

• The program explicitly supports career development options for early-career investigators (with mentorship).

• Pre-application requirements and peer review support transparency in mechanism expectations.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet released. The pre-announcement states that FOAs containing specific pre-application and application deadlines will be posted on Grants.gov and through the eBRAP portal once available.

• Funding start: After successful review, awards typically begin in the fiscal year following announcement (FY26), but exact start dates are not yet published.

Where does this funding come from?

Funding for TBDRP is provided by the Fiscal Year 2026 Defense Appropriations Act, and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (CDMRP).

Who is eligible to apply?

Eligibility varies by mechanism. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms.

• Career Development Option has specific requirements:

  • PI must be within 10 years of terminal degree (with exceptions for residency/family leave)

  • Mentor must be experienced (≥5 year track record in tick-borne disease research)

What companies and projects are likely to win?

Projects that are highly innovative, directly related to the defined focus areas, and translational in nature (with clear clinical relevance) are likely to be competitive. Specifically:

• Approaches that address persistent Lyme disease, novel diagnostics, and novel therapeutic strategies

• Research that demonstrates strong rationale or preliminary data aligned with CDCMRP priorities

• Early-career investigators partnered with experienced mentors (for Career Development Option)

Are there any restrictions I should know about?

• Clinical trials cannot be supported under these mechanisms; human studies are permitted where applicable.

• Full application submission is by invitation only after pre-proposal review.

• Mechanism‐specific eligibility and focus area alignment are strict and will be enforced in the FOA.

How long will it take me to prepare an application?

Preparation time varies significantly by mechanism and institutional support, but given the requirement for pre-proposals, preliminary data, and alignment with specific focus areas, investigators should plan for 6–12 weeks of preparation once the FOA is released. This accounts for drafting, internal review, and compliance checks prior to pre-application submission.

How can BW&CO help?

BW&CO can help you:

• Interpret and map your research to specific TBDRP focus areas

• Develop pre-proposal drafts and strategic research narratives

• Identify data needs and plan for compliant application packages

• Coordinate mentor relationships for career development submissions

• Set milestones to meet pre-application and full application deadlines

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Pancreatic Cancer Research Program (PCARP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Pancreatic Cancer Research Program (PCARP) is anticipated to issue multiple funding opportunities to accelerate impactful research in pancreatic cancer, spanning early detection, supportive care, risk characterization, access to care, metabolic dysregulation, tumor development, biomarkers, and new therapeutics. Investigators should begin planning now—formal Funding Opportunity Announcements (FOAs), deadlines, and application requirements will be posted on Grants.gov once released. This pre-announcement does not obligate funding but signals that awards will be available in FY26.

How much funding would I receive?

Funding varies by mechanism:

• Focused Pilot Award: Up to $300,000 total costs over up to 2 years.

• Idea Development Award: Up to $700,000 total costs over up to 3 years (standard) or $950,000 total costs with Partnering PI Option.

• Translational Research Partnership Award: Up to $1.1 million total costs over up to 3 years.

What could I use the funding for?

Funding supports research that directly addresses one or more of the following PCARP Focus Areas:

Scientific & Clinical Focus Areas

• Early detection research

• Identification and characterization of risk

• Supportive care, quality of life, and patient perspectives

• Healthcare access barriers and care delivery challenges

• Metabolic disruptions (including diabetes, cachexia)

• Tumor development from precursor lesions to metastasis

• Biomarkers for response prediction and management strategies

• Novel therapeutic targets and approaches

Each award mechanism may have specific constraints on what types of work it can support (e.g., some do not fund clinical trials or basic research).

Are there any additional benefits I would receive?

• Early insight into programmatic priorities via this pre-announcement.

• Access to eBRAP system for managing pre-applications.

• Email subscription updates when official FOAs are released.

What is the timeline to apply and when would I receive funding?

• Pre-announcement published: February 12, 2026.

• Official FOAs: To be posted on Grants.gov (dates not yet announced).

• Submission Deadlines: Will be specified in each FOA (pre-application and full application deadlines).

• Funding Start: Following review, award negotiation, and execution (typical CDMRP cycle timing, exact months TBD).

Where does this funding come from?

PCARP is funded through the FY26 Defense Appropriations Act and managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) as part of the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Focused Pilot Award: Investigators at any career level, including postdoctoral and clinical fellows.

• Idea Development Award: Independent investigators at any career stage; early-career investigators may partner with experienced PIs.

• Translational Research Partnership Award: Independent investigators; postdoctoral/clinical fellows are not eligible.

What companies and projects are likely to win?

Projects most competitive for PCARP will:

• Directly address one or more specified focus areas with strong scientific rationale.

• Demonstrate innovation and potential impact on pancreatic cancer outcomes.

• Align with mechanism goals (e.g., pilot studies for early-stage ideas, partnerships for translational work).

• Include appropriate preliminary data when required.

Are there any restrictions I should know about?

• Focused Pilot Award: No basic research, pre-clinical animal studies, or clinical trials.

• Idea Development & Translational Awards: Clinical trials and some animal work may be restricted or defined in FOA; check carefully.

• Pre-proposal or letter of intent submission is required prior to full application for many mechanisms.

How long will it take me to prepare an application?

Time depends on mechanism and data readiness:

• Focused Pilot Award: Plan ~4–8 weeks for a competitive pre-application and research plan.

• Idea Development & Translational Awards: With required preliminary data, plan ~8–16+ weeks to assemble data, collaborators, and a strong proposal.

Start early given the expected complexity of CDMRP applications.

How can BW&CO help?

BW&CO can help you:

• Interpret future FOA requirements and priorities.

• Structure pre-applications/letters of intent for maximum impact.

• Craft narrative, budget justification, and compliance sections.

• Align scientific aims with program focus areas to increase competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Lupus Research Program (LRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP’s FY26 Lupus Research Program (LRP) pre-announcement signals anticipated funding opportunities supporting innovative, high-impact lupus research aimed at understanding, preventing, diagnosing, and treating lupus, as well as improving the quality of life for individuals living with lupus. This pre-announcement does not include application deadlines or guarantee funding — the official Funding Opportunity Announcements (FOAs) will be posted on Grants.gov with formal deadlines and requirements. Investigators should begin planning now to align with expected FY26 mechanisms and program goals.

How much funding would I receive?

The pre-announcement outlines multiple award mechanisms with specified maximum total costs:

• Idea Award – up to $300,000 (2 years)

• Impact Award – up to $1,000,000 (4 years)

• Transformative Vision Development Award – up to $250,000 (2 years)

• Transformative Vision Award – up to $2,000,000 (4 years)

What could I use the funding for?

Funding must support research aligned with one or more LRP focus areas:

Biological & Clinical Research

• Mechanisms of lupus disease and pathobiology

• Genetic, epigenetic, and gene–environment interaction studies

• Disease heterogeneity, presentations, and outcomes
  Applies to Idea & Impact Awards

Quality of Life & Intervention Studies

• Addressing social determinants of health

• Nutrition, symptom control, comparative effectiveness

• Outcomes research and patient-reported outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Innovative Health Care Delivery Models

• Models improving lupus outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Are there any additional benefits I would receive?

• Mechanism clarity ahead of FOAs allows early planning.

• Subscribe to email updates through eBRAP for timely notifications when FOAs are released.

• Being positioned early can improve competitiveness.

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: February 11, 2026.

• Formal FOAs — will be posted on Grants.gov with official pre-application and full application deadlines.

• Investigators must submit a pre-application through eBRAP prior to the pre-application deadline specified in the FOAs.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act appropriated to the Congressionally Directed Medical Research Programs (CDMRP) and managed by the Defense Health Agency Research & Development and Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility is defined by mechanism:

• Idea Award: Investigators at or above postdoctoral level.

• Impact & Transformative Awards: Investigators at or above Assistant Professor (or equivalent).

• Team Requirements: Transformative mechanisms must include at least one lupus consumer advocate as part of the research team.

What companies and projects are likely to win?

Projects that:

• Align tightly with the specified focus areas.

• Demonstrate high innovation and impact potential.

• Involve strong preliminary data (as required for Transformative Vision Award).

• Include meaningful involvement of lupus consumer advocates (for transformative mechanisms).

Are there any restrictions I should know about?

• This pre-announcement is not a funding commitment; only the FOAs establish requirements and obligations.

• Applications cannot support clinical trials in Idea or Impact Awards; Transformative Vision Awards may support clinical trials but not animal studies.

• Transformative Vision Development Awards cannot support clinical trials or animal studies.

How long will it take me to prepare an application?

Preparation time depends on mechanism and complexity, but begin planning now — especially for pilot data and consumer engagement for transformative mechanisms. Historically, competitive CDMRP applications often require several weeks to months of focused preparation.

How can BW&CO help?

BW&CO can:

• Develop alignment narratives tied to LRP focus areas.

• Assist with preliminary data framing and research strategy articulation.

• Craft strong consumer advocacy integration plans.

• Ensure conformity with CDMRP review criteria once FOAs are released.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Breast Cancer Research Program (BCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Breast Cancer Research Program (BCRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), has released a Pre-Announcement for anticipated Fiscal Year 2026 (FY26) funding opportunities to support innovative, high-impact research aimed at ending breast cancer for Service Members, Veterans, their families, and the general public. This pre-announcement is intended to let investigators plan and develop proposals before the full Funding Opportunity Announcements (FOAs) are posted on Grants.gov. The government does not guarantee awards based on this document alone. FOA release dates, pre-application, and application deadlines will be announced on Grants.gov and eBRAP. Driven investigators should begin conceptualizing competitive approaches immediately.

How much funding would I receive?

The Pre-Announcement outlines anticipated award types with specified maximum total costs for FY26:

Breakthrough Award

• Level 1: up to $750,000 (single PI) or $1.25M (partnering PIs)

• Level 2: up to $1.65M (single PI) or $2.5M (partnering PIs)

• Population Science (Level 2): up to $2.5M (single) or $3.35M (partnering)

• Level 3: up to $5.6M (single) or $7M (partnering)

• Level 4: up to $21M
  (Breakthrough Awards range from early high-risk ideas to transformative approaches.)

Other Anticipated Mechanisms

• Era of Hope Scholar Award: up to $4.9M

• Clinical Research Extension Award: up to $7M (single) / $8.4M (partnering)

• Transformative Breast Cancer Consortium Award: up to $35M

• Transformative Breast Cancer Consortium Development Award: up to $140,000
  (These awards support early-career investigators, ongoing clinical research, and large multi-project consortia.)

What could I use the funding for?

Funded research must address one or more overarching challenges critical to ending breast cancer:

Topic Areas / Research Aims

• Primary prevention of breast cancer

• Determinants of initiation, risk, or susceptibility

• Distinguishing lethal vs. non-lethal tumors

• Solutions to overdiagnosis/overtreatment

• Pathways driving tumor growth and metastasis

• Mechanisms of dormancy and lethal recurrence

• More effective, less toxic treatments

• Reducing mortality from metastatic disease

Mechanism-Specific Uses

• Breakthrough Awards: high-risk/high-reward or translation-focused research

• Era of Hope Scholar Award: early-career leadership and innovation

• Clinical Research Extension: extending clinical data collection and analysis

• Consortium Awards: integrated multi-project collaborations toward transformative goals

(Mechanism scopes will be confirmed in the FOAs.)

Are there any additional benefits I would receive?

Participating teams may benefit from:

• Collaborative frameworks with consumer advocates required on some mechanisms

• Access to eBRAP support and templates for submission guidance

What is the timeline to apply and when would I receive funding?

• Pre-Announcement Released: February 2026 (no exact FOA deadlines yet)

• FOAs and deadlines: Will be posted on Grants.gov and eBRAP once finalized.

• Plan: Prepare project concepts now; watch Grants.gov and eBRAP for pre-application and application due dates, which may be weeks to months after FOA publication. Award start dates typically follow after review and appropriation obligations.

Where does this funding come from?

This funding is provided by the FY26 Defense Appropriations Act under the Department of Defense’s Congressionally Directed Medical Research Programs, specifically appropriated for breast cancer research.

Who is eligible to apply?

Eligibility varies by mechanism but generally includes:

• Investigators at all academic levels or equivalent (Breakthrough, Clinical Extension)

• Independent investigators (higher level awards)

• Teams including consumer advocates for specified awards

• Exact eligibility will be detailed in each FOA.

(Final eligibility criteria are determined in the FOAs.)

What companies and projects are likely to win?

Competitive proposals typically:

• Address key overarching challenges defined by BCRP

• Demonstrate innovation, clinical relevance, and impact

• Include translational pathways or transformative potential

• Meet mechanism-specific expectations (e.g., data access plans, interdisciplinary teams)

Are there any restrictions I should know about?

• This pre-announcement is not a FOA and does not guarantee funding.

• Final applications must conform to Grants.gov FOAs once released.

• Mechanism specific limits on clinical trials and preliminary data requirements will be in each FOA.

How long will it take me to prepare an application?

Preparation time varies by project complexity, but given the breadth of mechanisms and expected competitive standards, begin planning now while awaiting FOAs:

• Concept refinement: ~2–4 weeks

• Team assembly & consumer advocate engagement: ~2–6 weeks

• Budget & prelim data planning: ~4–8+ weeks depending on scope

How can BW&CO help?

BW&CO can assist with:

• Translating BCRP FOA language into tailored project responses

• Drafting narrative, budget justification, and impact sections

• Aligning your concept with mechanism-specific review criteria

• Incorporating consumer review perspectives where required

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

DIU - Sensors and Seekers For Fire Control

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now — Responses due February 13, 2026 at 23:59:59 US/Eastern for Deorbit as a Service, a high-priority Defense Innovation Unit (DIU) Commercial Solutions Opening (CSO) to solve a strategic orbital debris and space sustainability challenge. This solicitation funds scalable autonomous technologies that can deorbit unprepared satellites safely and reliably, reducing orbital congestion and enabling future space operations. This is a rare fast-paced opportunity to partner with the U.S. Department of Defense (DoD) using flexible Other Transaction Authority with potential follow-on production contracts without further competition — massive market potential.

You’ll submit a Solution Brief that directly addresses specific detection, tracking, and discrimination capabilities using commercial sensing technologies. If selected, DIU can award a Prototype Other Transaction (OT) agreement and potentially a follow-on production contract if the prototype is successful.

How much funding would I receive?

DIU does not publicly list a fixed award size on this solicitation page. Funding amounts for DIU prototype OT agreements vary based on technical scope and negotiated project budgets with selected vendors.

What could I use the funding for?

Funding may be used to develop and demonstrate prototypes that meet the Government’s technical needs, including:

A. Sensor System Development

• LIDAR/LADAR, EO/IR, RF, or combined modalities that enable high-fidelity detection, tracking, and discrimination under extreme conditions.

B. Fire Control Enablement

• Systems capable of providing real-time, fire-control-quality tracking data (range, angular resolution, update rates) for engagements against ICBMs or hypersonic glide vehicles.

C. Prototyping & Demonstrations

• Bench-top or lab demonstrations within ~6–9 months.

• On-orbit demonstrations as a hosted payload within ~12–24 months (if applicable).

Are there any additional benefits I would receive?

Yes. Commercial companies participating through DIU can gain:

• Access to DoD customers and mission partners who care about real outcomes.

• A potential follow-on production contract without a new competition after satisfactory prototype completion (per 10 U.S.C. §4022(f)).

• Exposure to broader government adoption via Success Memos that other DoD entities can use.

What is the timeline to apply and when would I receive funding?

• Application Deadline:
  🔹 February 17, 2026 at 23:59:59 US/Eastern Time

  Typical DIU CSO timeline:

  • Solution Brief submission → evaluation

  • ~30 days to get invited to pitch if selected

  • Contracts negotiated and awarded typically within ~60–90 days after selection (varies).

  Prototype execution milestones generally include lab demos within 6–9 months and potential on-orbit demos within 12–24 months, as outlined by this project.

Where does this funding come from?

The funding is provided through the Department of Defense (DoD) via the Defense Innovation Unit (DIU) using its Commercial Solutions Opening (CSO) process under Other Transaction (OT) Authority (10 U.S.C. 4022).

Who is eligible to apply?

U.S. and international vendors with relevant sensor and seeker technologies.

• Companies must satisfy OT authority requirements per 10 U.S.C. 4022(d) (e.g., participation of nontraditional firms, small business involvement, or non-government funding share).

No specific size, revenue, or TRL ceiling is listed, but solutions must be technically relevant and commercially viable.

What companies and projects are likely to win?

Winners will propose solutions that demonstrate:

• High-performance sensing and discrimination across threat scenarios.

• Commercially scalable designs (design for manufacturability and low unit cost).

• Plan for integration into aerospace or space platforms.

• Capacity to meet aggressive prototyping timelines.

Companies offering modular, commercially producible systems that leverage dual-use technology trends have a competitive edge

Are there any restrictions I should know about?

Must comply with 10 USC 4022 OT authority requirements for award eligibility.

• All submissions must certify no Controlled Unclassified Information (CUI) unless expressly allowed.

• Awarded agreements will include compliance language for Section 889 of the 2019 NDAA.

How long will it take me to prepare an application?

Most DIU Solution Briefs are 5 pages or ~15 slides and should specifically address the challenge and key solution attributes. Preparation time depends on your level of readiness but planning 2–6 weeks to align technical, programmatic, and compliance content is reasonable.

How can BW&CO help?

BW&CO can support you to:

• Translate DIU requirements into a winning Solution Brief that aligns with your tech and DoD’s need.

• Craft compelling narrative for detection, tracking, and fire-control relevance.

• Map technical milestones and prototyping costs for rapid award.

• Prepare compliant attachments (e.g., SAM/SAM.gov, CAGE, IP/Section 889 compliance).

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.